Products
-
‘We are going to have to be agile’: Butler
- Fri Sep 18
Desperate to fill the pending gap left by AZ’s Zoladex leaving the PBS, the government demonstrates how fast it can move when patient access is threatened.
Read more -
Targeted MND therapy gains fast PBS berth
- Fri Sep 11
Fast-tracked through TGA and PBS, the first therapy for a rare form of ALS is to be funded on the PBS four months after TGA registration.
Read more -
Expansions mark strong month for September PBS
- Wed Sep 2
Five of the eight changes to the PBS this month were pre-announced, but what else changed, and how are new listings tracking?
Read more -
10-year battle for broad access ends for Keytruda
- Mon Aug 31
Leading immunotherapy Keytruda PBS funded for broad use at clinician discretion as three more therapies move to join the world-leading trend.
Read more -
First targeted lupus treatment fast-tracked to PBS
- Mon Aug 31
PBS funds the first targeted treatment for lupus‑related kidney disease after the PBAC offered Roche a fast-tracked pricing pathway.
Read more -
Aussie patients wait for homegrown therapy
- Wed Aug 26
Europe secures access to the first and only approved Rett syndrome treatment joining the US and Canada, but there’s no sign of a TGA dossier.
Read more -
PBAC doubles-down on its value demands
- Mon Aug 24
PBAC recommended two out of three submissions, its decision-making demonstrating how even with high unmet need, price is what matters most.
Read more -
UK fast-funding decision puts Australia to shame
- Mon Aug 24
NICE approves broad NHS coverage for weekly injectable four months after Australia failed to ink a deal to fund the same weekly therapy.
Read more